Walleye Capital’s PTC Therapeutics PTCT Stock Holding History

Walleye Capital’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-800	Closed	-$60.8K	–	4861
2025 Q4	$60.8K	Buy	+800	New	+$58.1K	﹤0.01%	4033
2024 Q2	–	Sell	-600	Closed	-$17.5K	–	5917
2024 Q1	$17.5K	Buy	+600	New	+$16.8K	﹤0.01%	4962
2023 Q2	–	Sell	-1,400	Closed	-$67.8K	–	4779
2023 Q1	$67.8K	Buy	1,400 +1,000	+250%	+$45.7K	﹤0.01%	3095
2022 Q4	$15.3K	Buy	+400	New	+$16.6K	﹤0.01%	2703
2020 Q1	–	Sell	-34,800	Closed	-$1.67M	–	1505
2019 Q4	$1.67M	Sell	34,800 -7,600	-18%	-$323K	0.11%	256
2019 Q3	$1.43M	Buy	42,400 +38,000	+864%	+$1.65M	0.09%	321
2019 Q2	$198K	Sell	4,400 -2,000	-31%	-$79K	0.02%	975
2019 Q1	$241K	Buy	+6,400	New	+$215K	0.04%	689

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Walleye Capital's PTCT Position: Q2 2026 in Review

Walleye Capital opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 19,522 shares worth $1.59M. The stake represents 0.01% of the portfolio and ranks #1722 among its holdings. This is a return to the name: Walleye Capital previously reported a position in PTCT as recently as Q4 2025.

Walleye Capital first reported a position in PTCT in Q2 2019 and has held it in 16 quarters since. The position peaked at $4.97M in Q4 2024. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Walleye Capital held 19,522 shares of PTC Therapeutics worth $1.59M as of Q2 2026.
PTC Therapeutics was a new Walleye Capital position in Q2 2026.
PTC Therapeutics made up 0.01% of Walleye Capital's portfolio in Q2 2026, its #1722 holding.
Walleye Capital first reported a position in PTC Therapeutics in Q2 2019 and has held it in 16 quarters since.
Walleye Capital's PTC Therapeutics position peaked at $4.97M in Q4 2024.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.